1. Home
  2. VALE vs REGN Comparison

VALE vs REGN Comparison

Compare VALE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VALE S.A.

VALE

VALE S.A.

HOLD

Current Price

$15.27

Market Cap

64.2B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$827.72

Market Cap

68.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALE
REGN
Founded
1942
1988
Country
Brazil
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.2B
68.8B
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
VALE
REGN
Price
$15.27
$827.72
Analyst Decision
Buy
Buy
Analyst Count
10
25
Target Price
$16.96
$830.16
AVG Volume (30 Days)
25.1M
565.1K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
5.71%
0.55%
EPS Growth
N/A
8.19
EPS
N/A
18.95
Revenue
N/A
$5,872,227,000.00
Revenue This Year
N/A
$12.45
Revenue Next Year
N/A
$10.13
P/E Ratio
$29.09
$44.35
Revenue Growth
N/A
20.82
52 Week Low
$10.58
$541.00
52 Week High
$17.94
$859.34

Technical Indicators

Market Signals
Indicator
VALE
REGN
Relative Strength Index (RSI) 55.70 65.31
Support Level $14.68 $732.04
Resistance Level $17.38 $847.00
Average True Range (ATR) 0.42 19.34
MACD 0.11 -3.02
Stochastic Oscillator 66.99 76.33

Price Performance

Historical Comparison
VALE
REGN

About VALE VALE S.A.

Vale is a large global miner and the world's largest producer of iron ore and pellets. In recent years, the company has sold noncore assets such as its fertilizer, coal, and steel operations to concentrate on iron ore, nickel, and copper. Earnings are dominated by its iron ore business. The base metals division is much smaller, consisting of nickel mines and smelters along with copper mines producing copper in concentrate. In 2024, Vale sold a minority 10% stake in its base metals business, likely the first step in separating base metals and iron ore.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: